Shares of CERo Therapeutics Holdings climbed after the immunotherapy company's lead drug candidate for the treatment of acute myeloid leukemia gained orphan drug designation from the Food and Drug ...

Investing.com -- CERo Therapeutics Holdings Inc (NASDAQ: CERO) stock surged 191.6% after the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for the company’s lead ...

SOUTH SAN FRANSCISCO, Calif., June 17, 2025-- CERo Therapeutics Holdings, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that ...

SOUTH SAN FRANSCISCO, Calif., June 11, 2025-- CERo Therapeutics Holdings, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that ...

SOUTH SAN FRANSCISCO, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to ...